Capivasertib, the selective and potent AKT inhibitor, can reduce radioresistance and improve the efficacy of radiotherapy in 3D cell cultures and the preclinical animal model, with a tumor-seeking nano-based drug delivery system. This evidence concerns the gene AKT1 and neoplasm.